Skip to content
lifestyle.side.cr
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Lexeo Therapeutics
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
August 5, 2026
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 19, 2026
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February
February 10, 2026
←
Previous Page
1
2